SCP-3459
Euclid
~
medium confidence
SCP-3459
Expected annual
$23.7M
One-time setup
$18.2M
Annual recurring
$22.2M
Personnel
23
One-time capital costs concentrated in secure BSL-3 construction, quarantine buildouts, laboratory setup, and initial monitoring platform (~$18.2M). Recurring annual operations driven by research/surveillance, staff wages, MTF readiness, legal/PR/insurance and global logistics (~$22.2M/yr baseline).
One-Time Capital Costs
Total: $18.2M
Annual Recurring Costs
Total: $22.2M/yr
Cost Scenarios
📊
Baseline
(baseline)
$22.2M/yr
Normal year with ongoing surveillance, research, staff costs, and routine operations without major incidents.
routine surveillance
no major outbreaks
steady research operations
🚨
Minor Incident
$23.2M/yr
Localized outbreak or cluster requiring limited MTF activation, extra decontamination, targeted testing and amplification.
localized cluster
single MTF deployment
heightened local testing/decontamination
🚨
Major Outbreak
$47.2M/yr
Multi-city outbreak with heavy media exposure, multiple MTF deployments, mass quarantines and emergency clinical/drug trials.
multi-city transmission
widespread media/political attention
initiation of emergency clinical programs
Personnel
23 total
| Role | Count | Notes |
|---|---|---|
| Human Moderators / Embedded Operators | 10 | [#3] Ten full-time trained social-engineering/psyops operators to run embedded accounts and moderation duties. |
| Research Scientist | 6 | [#11, #12, #16] BSL-3-capable scientists (microbiologists/neuroscience/epidemiology) supporting research and surveillance. |
| Laboratory Technician | 4 | [#11, #12] Technicians and lab techs for sample processing, sequencing, and BSL-3 facility operations. |
| Biosafety Officer | 1 | [#12] Dedicated biosafety officer for BSL-3 compliance and validation. |
| Administrative Staff | 2 | [#3, #23] Admin/liaison personnel supporting legal/platform coordination, scheduling, and OPSEC compliance. |
Confidence Notes
Analyst notes provide detailed line-item ranges enabling mid-range estimates, but wide uncertainty remains around outbreak frequency, scale of legal/insurance exposures, and R&D/clinical pathways; thus medium confidence.